12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Edarbyclor azilsartan medoxomil/chlorthalidone regulatory update

FDA approved an NDA from Takeda for Edarbyclor azilsartan/chlorthalidone to treat hypertension. The product is a fixed-dose combination of azilsartan,...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >